Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab. - Physician's Weekly


Advertisement

Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab.

Oct 23, 2023

ABOUT THE CONTRIBUTORS

  • Mie Jin Lim

    Division of Rheumatology, Department of Internal Medicine, College of Medicine, Inha University, Incheon, Korea.

    Kyong-Hee Jung

    Division of Rheumatology, Department of Internal Medicine, College of Medicine, Inha University, Incheon, Korea.

    Seong-Ryul Kwon

    Division of Rheumatology, Department of Internal Medicine, College of Medicine, Inha University, Incheon, Korea.

    Won Park

    Division of Rheumatology, Department of Internal Medicine, College of Medicine, Inha University, Incheon, Korea.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.